Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Huoxin pill for post-PCI angina pectoris
ChiCTR2100051805Phase 4Recruiting
- Sponsor
- Yueyang Hospital of Integrated Traditional Chinese and Western Medicine
- Start
- Oct 2019
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Huoxin Pill in atherosclerotic disease, angina pectoris and coronary arteriosclerosis, sponsored by Yueyang Hospital of Integrated Traditional Chinese and Western Medicine. Primary endpoint: Nitroglycerin reduction rate. Started Oct 2019; status: recruiting.
02
Drugs
Huoxin Pill
03
Conditions
atherosclerotic diseaseangina pectoriscoronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR2100051805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051805.